Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
level two looking thin . GO GOVX $$$$$
She wants to blow people start slapping that ask limit orders are the only thing holding us back now
Todays buy and sell action on GOVX so far is 1.8 Million BUYS 264k SELLS Monster run in the making. Its been this pattern for last month or so. And the volume is 10x as high as the previous months. GOVX six million market cap is absurdly cheap. GOVX is getting ready to break three years high will be trading between .30-.50 sooner than later.
HIV Therapeutic Vaccine (“Functional Cure” Program) – In March 2017, GeoVax began a collaboration with American Gene Technologies International, Inc. (AGT) with the goal of developing a functional cure for HIV infection through AGT’s gene therapy technology in combination with GeoVax’s HIV vaccine. The Company expects AGT to file an Investigation New Drug (IND) application in early 2018 and to initiate human clinical trials of the companies’ combined technologies in mid-2018.
Zika Vaccine – In June 2017, at the American Society for Microbiology (ASM) conference (ASM MICROBE 2017) in New Orleans, LA, and later in August at the 5th Annual Meeting of Cambridge Healthtech Institute, Immuno-Oncology Summit, in Boston, MA, as well as in October 2017, at the 18th World Vaccine Congress Europe in Barcelona, Spain, GeoVax presented data showing that a single dose of its Zika vaccine (GEO-ZM02) gave 100% protection in mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. This is the first report of i) a Zika vaccine based on the ZIKV non-structural (NS1) protein, and ii) single-dose protection against ZIKV using an immunocompetent lethal mouse challenge model. The vaccine was tested at the Centers for Disease Control and Prevention (CDC) in Ft. Collins, CO with funding from the CDC. GeoVax’s approach to a Zika vaccine is unique in that it uses the non-structural protein NS1 instead of the commonly used structural proteins for immunogens, and thus avoids potential Antibody Dependent Enhancement (ADE) of infection, a safety concern for Zika vaccines based on structural proteins.
I agree there was a lot more hype before when we hit 460 and then took a dive after the soft launch . Volume is way down I got in last time at .2 and the volume was quadruple and it was moving I think everyone is just as frustrated as I am with INMG . We’ll all I can do is wait and keep posting go INMG $$$ and keep my fingers crossed that may work . Lol
It’s been going like this weeks they could have accumulated millions of shares by now
The only thing that makes sense to me as to why they would benefit holding it back is so that they could load more for cheaper but that would mean the same people would have to be buying and putting those little 500 lots out of sells to hold it down and buy more . She’s gonna blow Eventually. It’s coming
That’s exactly what my friend said who got me to buy into this. Then I started researching and this company has some real potential. Great team and big possibility. I’m long and strong here it just gets so frustrating sometimes like just now when a 500 lot holds us back after close to 500k buys . Lol we’ll get there I’m not tripping at all .
Your probably right but it’s so obvious the sells are weak in here and fabricated for the most part . She’s gonna blow soon ! Should have already go GOVX $$$
100k ask slaps all over the place today they can’t hold it back forever . Go GOVX $$$$
GOVX VACCINE PIPRLINE INCLUDES 11 VACCINES
HIV Vaccine Functional Cure VACCINE
ZIKA FUNCTIONAL CURE VACCINE
HIV PHASE 2B CLAUDE B COMMENCING SOON
HIV PH1 CLAUDE C VACCINE
HEPITIIS VACCINE OUTBREAK IN CA ONGOING
EBOLA VACCINE
LASSA VACCINE
MARSBURG VACCINE
CANCER IMMUNOTHERAPY VACCINE'S
MALARIA
MARSBURG
Go GOVX $$$
GeoVax to Present at the Third International Conference on Vaccines Research and Development
Presentation to Focus on Development of Zika, Ebola and Lassa Fever Vaccines
ATLANTA, GA--(Marketwired - Nov 13, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will deliver a talk, entitled "Development of Novel and Safe Single-Dose Vaccines; Preclinical Efficacy Data for Zika, Ebola and Lassa Fever," during the Third International Conference on Vaccines Research and Development, on Tuesday, November 14 in Washington, DC.
Dr. Guirakhoo will discuss GeoVax's vaccine platform which utilizes its recombinant Modified Vaccinia Ankara (MVA) vector to express foreign antigens on virus-like particles (VLPs) in the person being vaccinated. The MVA-VLP platform has several advantages including the ability to use single inoculations to achieve protection. Single-dose protection is a favorable characteristic of a vaccine for emerging infectious disease outbreak response, given the speed of spread of pathogens and the impracticality of multi-dose regimens in the under-resourced settings where outbreaks often occurs.
In studies for Ebola, Lassa and Zika, a single dose of GeoVax's vaccine fully protected animals against a lethal challenge. During his talk, Dr. Guirakhoo will present the latest data from these studies, as examples of the broad utility of the MVA-VLP platform for other indications. These three vaccines are now ready to enter human clinical trials. The platform which has previously shown to elicit both durable antibody and T cell responses against HIV in several clinical trials, is also currently being investigated for use against malaria, chronic hepatitis B infection, and in cancer immunotherapy in combination with immune checkpoint inhibitors.
GeoVax's MVA-VLP platform technology is built upon a 4th generation MVA vector system that is improved for high expression and stable transgenes during manufacture. It has the advantages of being a live replication-competent vector in avian cells for manufacturing, yet replication-deficient in mammalian cells for vaccination, thus inherently safe. Importantly, MVA vaccines elicit protective T cell as well as antibody responses in animals and humans. The MVA platform can be combined with the potent immunogenicity of VLPs or be used to express proteins in their native multimeric conformations enabling vaccines that induce full protection after a single dose. The safety and immunogenicity of the platform was first validated in animal and human studies using DNA and MVA-VLP-HIV vaccines and further expanded for developing vaccines against emerging pathogens, endemic diseases, chronic infections and cancer.
Ok thank you very much
Is there a time frame on phase III ?
Anyone know why they offered warrants to buy shares at 3$ not too long ago and the price is at 2$ I’m looking to invest here but that doesn’t sound very good .
I? feel the same this thing is going to blow up soon under a dime won’t last long imo . Too much positivity going on here and it’s so undervalued its ridiculous.I? don’t know what’s up with those fake sales of 10 shares or 40 shares who’s going to pay $4.95 commissions for .70 worth of holdings . Doesn’t make sense I? think the MMs needed to put some red on the board to justify bringing the pps down someone is accumulating the crap out of this . Definitely something up . Go GOVX $$$$ long and strong
Total buys Friday was 3.5 million plus and sells were 426k this thing is being accumulated big time under .10 this is going to explode very soon . It’s unbelievably we could only go up less than 1% on that volume imbalance .
A $1.00 Price gives GOVX about a 65 Million Market cap for one of the most diverse HIV vaccines platforms in the world. Tim Monath Harriet L Robinson Farshad Guirakhoo, Ph.D., Chief Scientific Officer for GOVX these are some of the top Vaccine scientist and HIV researchers in the world. Also Stanley A. Plotkin, MD, Barney S. Graham, MD, PhD and Olivera (Olja) J. Finn, PhD. They have a world renowned team in place.
11 vaccine pipeline Single shot HIV cure vaccine and single Shot Zika cure vaccine. Partnerships with the CDC, NIH, HVTN,Scripps research institute, Maryland school of medicine, Duke University, National Institute of Allergy and Infectious Diseases (NIAID). American Gene Technologies International, University of North Carolina at Charlotte, Georgia State University Research Foundation, University of Pittsburg, Shenzhen Graduate School of Peking University, Burnet Institute of Australia.
What is key here is the personal and partnerships. The company has received over 50 Million dollars in non-dilutive support from research grants "Other Corporate Developments – In December 2016, we announced the appointment of Farshad Guirakhoo, PhD, as our new Chief Scientific Officer to succeed Harriet Robinson, PhD, who remains as Chief Scientific Officer Emeritus and director of our HIV vaccine program. And in January 2017, we announced the formation of a Scientific Advisory Board composed of world-class scientists including Thomas Monath, MD; Stanley Plotkin, MD; Barney Graham, MD, PhD; Scott Weaver, PhD; and Olivera Finn, PhD'This stock is trading at .045 Yes thats four and half cents and a market cap under 3 Million. 11 Vaccines in the pipeline.
This is the most undervalued biotech stock on any exchange. They are fully reporting on the OTCQB. I see this stock climbing to a dollar near term. People investing at these levels will can make Return on Investment than can see potential 50x-100x Gains. $50,000-$100,000.00 dollar investment can possibly make you a multi millionaire many times over. This stock is going to see a see parabolic move soon. The writing is on the wall.
I? agree 100% then this is going to go way the fu$k up!!! Up up and away !
I? agree it’s great to hit the high let’s see if we can hold past it really no serious seller that’s a good sign . Go GOVX
799 come on they just don’t want to see this thing breakout . Go GOVX $$$
They can’t hold it back forever go GOVX slap that ask !!!!
I? agree these sellers can take their beer money they just don’t see the big picture here and the majority of the holding are institutional holding for dollars not pennies . The combination only has one outcome .Go GOVX $$$
Breakout is imminent!!! Go GOVX $$$
Why GOVX is going to multiple dollars per share.
Vaccine Development Update:
Continued Validation of MVA-VLP Vaccine Platform - GeoVax's product pipeline is based on its Modified Vaccine Ankara (MVA) Virus-Like Particle (VLP) vaccine platform. This platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control target infections.
As discussed in more detail below, the Company's original application of its technology was in developing preventive HIV vaccines. More recently it expanded to preventive vaccines for Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections and cancers.
GeoVax continues to build an impressive data set for its MVA-VLP platform, now with preclinical proof-of-concept in four disease indications (HIV, Zika, Lassa, Ebola), and excellent safety and immunogenicity in clinical trials of its HIV vaccine involving 500 individuals. These data provide strong rationale for expecting clinical efficacy for the current vaccine development programs, as well as encouragement for future pipeline expansion to additional disease indications.
HIV Preventive Vaccines - GeoVax's most advanced program is a prophylactic vaccine (designated GOVX-B11) for the clade B subtype of HIV, the most common form of HIV in North America, Western Europe, Australia and Japan. This program has successfully completed phase 1 and phase 2a human clinical trials, which were conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Diseases (NIAID).
In January 2017, the HVTN initiated a phase 1 human clinical trial of GOVX-B11, (trial designation HVTN 114) to evaluate the durability of immune responses elicited by GOVX-B11 and the effects of late boosts (additional vaccinations) on the antibody responses elicited by the GOVX-B11.
The next planned clinical trial of GOVX-B11 will be an additional Phase 1 trial, evaluating the safety and immunogenicity of a prime-boost regimen of GOVX-B11 with and without two additional protein boosts. This trial will be conducted by HVTN with funding from NIAID; the Company anticipates a start date in mid-2018. Both this trial and HVTN 114 will contribute data critical in determining the regimen to be used in a future phase 2b efficacy trial. During 2017, GeoVax continued its work under a NIAID contract of up to $7.8 million for production of the DNA component of GOVX-B11 intended for the later-stage clinical trials.
GeoVax also continued preclinical work funded by grants from NIAID for its vaccine for the clade C HIV subtype prevalent in Africa. In October 2017, the Company reported the elicitation of a key precursor for broadly neutralizing antibody for the HIV CD4 binding site, a significant advance in HIV vaccine development. The findings were published in the peer-reviewed open access journal PLOS ONE, and can be viewed at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0177863.
HIV Therapeutic Vaccine ("Functional Cure" Program) - In March 2017, GeoVax began a collaboration with American Gene Technologies International, Inc. (AGT) with the goal of developing a functional cure for HIV infection through AGT's gene therapy technology in combination with GeoVax's HIV vaccine. The Company expects AGT to file an Investigation New Drug (IND) application in early 2018 and to initiate human clinical trials of the companies' combined technologies in mid-2018.
Zika Vaccine - In June 2017, at the American Society for Microbiology (ASM) conference (ASM MICROBE 2017) in New Orleans, LA, and later in August at the 5th Annual Meeting of Cambridge Healthtech Institute, Immuno-Oncology Summit, in Boston, MA, as well as in October 2017, at the 18th World Vaccine Congress Europe in Barcelona, Spain, GeoVax presented data showing that a single dose of its Zika vaccine (GEO-ZM02) gave 100% protection in mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. This is the first report of i) a Zika vaccine based on the ZIKV non-structural (NS1) protein, and ii) single-dose protection against ZIKV using an immunocompetent lethal mouse challenge model. The vaccine was tested at the Centers for Disease Control and Prevention (CDC) in Ft. Collins, CO with funding from the CDC. GeoVax's approach to a Zika vaccine is unique in that it uses the non-structural protein NS1 instead of the commonly used structural proteins for immunogens, and thus avoids potential Antibody Dependent Enhancement (ADE) of infection, a safety concern for Zika vaccines based on structural proteins.
Preclinical efficacy of GEO-ZM02 was published in the peer-reviewed open access journal Scientific Reports by Nature Research under the title of "A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model" and can be viewed at www.nature.com/articles/s41598-017-15039-8.
Also in June, the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded GeoVax a Small Business Innovative Research (SBIR) grant of $600,000 to support advanced preclinical testing, including non-human primate studies, for its Zika vaccine development program in preparation for a Phase 1 human clinical study.
Lassa Fever Vaccine - In July 2017, GeoVax reported a significant step forward in the development of a vaccine candidate for protection against Lassa hemorrhagic fever virus (LASV). Efficacy testing in a murine challenge model (using a chimeric LASV reassortant) showed a single intramuscular dose of GEO-LM01, provided 100% protection to mice infected with a lethal dose of the challenge virus directly delivered into the brain. The study was conducted, and successfully repeated, at the Institute of Human Virology at the University of Maryland School of Medicine. Also in July, the Company expanded its LASV vaccine development efforts through a collaboration with The Scripps Research Institute located in San Diego, CA.
In October, at the International Society for Vaccines, at the Institute Pasteur in Paris, France, GeoVax presented updates on efficacy data of its single dose vaccine for Lassa fever virus.
Earlier, a single dose of GeoVax's Ebola (EBOV) vaccine was shown to protect 100% of rhesus monkeys against death. GeoVax is also developing vaccines against Sudan virus (SUDV) and Marburg virus (MARV), two other lethal hemorrhagic fever viruses for which no effective vaccine currently exists. In addition to developing the four individual hemorrhagic fever vaccines (EBOV, LASV, SUDV, MARV),
the Company's goal is to combine the vaccines into a single tetravalent vaccine to provide broad protection for individuals at-risk for these viruses. In October, together with its collaborators at Rocky Mountain Laboratories of NIH, GeoVax submitted a manuscript for publication to a prestigious peer reviewed Journal describing efficacy data for its MVA-VLP-Ebola vaccine.
Immuno-oncology Program - In August 2017, at the 5th Annual Meeting of Cambridge Healthtech Institute, Immuno-Oncology Summit, in Boston, MA, as well as in October, at the 18th World Vaccine Congress Europe in Barcelona, Spain, GeoVax presented preliminary results from studies of its cancer vaccine in collaboration with ViaMune, Inc. The studies were performed by the laboratory of Dr. Pinku Mukherjee, PhD, at the University of North Carolina at Charlotte. GeoVax and ViaMune are each developing products that target an abnormal form of the cell surface-associated protein, Mucin 1 (MUC1), which is overexpressed in metastatic cancers (e.g. breast, pancreatic, lung, and ovarian cancers) and circulating tumor cells and which is often used as a diagnostic marker for cancer progression. In a human MUC1 colon adenocarcinoma mouse tumor model, groups of hMUC1 transgenic mice with established tumors were treated with MTI (ViaMune's synthetic vaccine), MVA-VLP-MUC1 (GeoVax's viral-vectored vaccine) or a combination of both. All treatment groups received an immune checkpoint inhibitor in the form of an anti-PD-1 antibody. The results from two studies indicate that a combined vaccine approach increases the therapeutic potential of anti-PD-1 therapy, giving excellent scientific justification to vigorously pursue additional investigation of this potential cancer vaccine.
Malaria Vaccine - In January, GeoVax initiated a program to develop a malaria vaccine using its MVA-VLP viral vector platform through collaboration with The Burnet Institute in Australia. The Company has completed construction of 4 vaccine candidates which have been shipped to Burnet Institute and are currently being evaluated in preclinical proof-of-concept studies.
Chronic Hepatitis B Immunotherapy - During the first quarter of 2017, GeoVax added Georgia State University and Peking University as collaborators to develop a therapeutic vaccine for chronic hepatitis B infection. Preclinical proof-of-concept studies are ongoing.
This can make you a multi millionaire if you invest 50k-100k at these levels. HIV Cure Vaccine is worth Billions in itself.
GOVX today had 2,200,000 buys and 640,000 sells . Shit is ready to pop they can’t hold it back forever .GO GOVX $$$$
I? agree this thing has some major potential .10 by tomorrow .25 to.50 near term target . Go GOVX $$$$$
Cutting through the resistance nicely in after hours this things should fly today . Go OSTK 50$ here we come !
Maybe just to show strength and value because the earnings really weren’t spectacular. Yeah with what’s going on with every other company that battles amazon for the space they look decent. but the real value is in T zero and block chain . He’s keeping the big news under wraps until he makes a final decision on things . He must know that whatever he has working is going to be huge and he’s thinking like everyone else would . Imagine if amazon would have done a buyback in the early days . He would be the richest man alive even though he already is he would be 1000 times richer . I’m sure will hear some big news soon in the weeks to come .after he pitches it to some of his billionaire friends . Lol
The whole t zero idea is about people participating in the tokens and the platform.I? don’t think it would benefit him in any way to try to make it private unless he was a really greedy guy . We’re all going to make a lot of money of this and that the bottom line .
When these sellers get out of the way this thing is going to have a huge run low float . Moves on air,go OSTK $$
Yeah decent close this things getting ready for a big run . Breakout is coming . Go GOVX $$$
And boom goes the dynamite!!! Go ostk$$$$ 50$ here we come .
Your looking at the wrong part of the chart maybe the five min chart. When you look at higher time frames it looks a lot better in a couple years this thing is going to be in the hundreds . Surprised maybe your zoom is broken you should have that checked out . Go OSTK $$$$
I? agree this thing is going to sky rocket tomorrow . Companies don’t issue stock dividends when their not making money and showing a really positive upside . That only comes when the books show extra money and you either do buy Back or dividends . Either way same outcome to the moon . Go OSTK $$$$
I? agree this thing is primed for a nice launch upward! Go GOVX $$$ hey trendsetter why don’t why don’t you sell some shorts I? dare you . Lol what a joke
One of the most diverse vaccine pipelines in the world 11 vaccines and counting single shot HIV Vaccine and Zika to commence in Humans soon and phase 2B for GOV-B11-Claude B, Cancer Immunotherapy vaccines. Top Universities and vaccine scientist including Monath, Frashad, Plotkin, and Graham and Harriet L Robinson one of the leading researchers in HIV vaccines development. This company is extremely undervalued at 3.7 Million Yes thats under a 4 Million Market cap and and about 65 Million Shares 1/3 of those shares are owned by Inst and Insiders and private placements. GOVX should see a .25-.50 Price and then a climb to dollars in 2018. I believe a $15.00-$25.00 price target by 2020
https://www.geovax.com/clinical-pipeline.html
Less
Aids Vaccine Research - GeoVax, Inc.
Aids Vaccine Research - GeoVax, Inc.
www.geovax.com